| Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, ... Thyroid 17 (4), 351-355, 2007 | 243 | 2007 |
| The Bethesda handbook of clinical oncology J Abraham, JL Gulley Lippincott Williams & Wilkins, 2022 | 165 | 2022 |
| Anti–PD-L1 treatment induced central diabetes insipidus C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, ... The Journal of Clinical Endocrinology & Metabolism 103 (2), 365-369, 2018 | 107 | 2018 |
| The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, ... Pancreas 50 (4), 469-493, 2021 | 105 | 2021 |
| Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis N Makita, T Iiri Thyroid 23 (2), 151-159, 2013 | 104 | 2013 |
| Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird Surgery 159 (1), 302-310, 2016 | 94 | 2016 |
| Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, ... Journal of bone and mineral research 31 (10), 1845-1854, 2016 | 93 | 2016 |
| Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, ... Endocrine-related cancer 23 (12), 899-908, 2016 | 82 | 2016 |
| Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, ... The Oncologist 25 (4), 290-300, 2020 | 80 | 2020 |
| High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma A Jha, D Taïeb, JA Carrasquillo, DA Pryma, M Patel, C Millo, ... Clinical Cancer Research 27 (11), 2989-2995, 2021 | 77 | 2021 |
| Emerging treatments for advanced/metastatic pheochromocytoma and paraganglioma M Ilanchezhian, A Jha, K Pacak, J Del Rivero Current Treatment Options in Oncology 21, 1-18, 2020 | 74 | 2020 |
| Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report JE Faris, AF Moore, GH Daniels Thyroid 17 (11), 1147-1149, 2007 | 74 | 2007 |
| The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related … J Schovanek, V Martucci, R Wesley, T Fojo, J Del Rivero, T Huynh, ... BMC cancer 14, 1-9, 2014 | 69 | 2014 |
| New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications S Jhawar, Y Arakawa, S Kumar, D Varghese, YS Kim, N Roper, F Elloumi, ... Cancers 14 (3), 594, 2022 | 65 | 2022 |
| PARP Inhibitors: The Cornerstone of DNA Repair--Targeted Therapies J del Rivero, EC Kohn Oncology 31 (4), 265-274, 2017 | 62 | 2017 |
| A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules ME Gatti-Mays, J Strauss, RN Donahue, C Palena, J Del Rivero, ... Clinical Cancer Research 25 (16), 4933-4944, 2019 | 57 | 2019 |
| Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants D Taïeb, GB Wanna, M Ahmad, C Lussey-Lepoutre, ND Perrier, S Nölting, ... The Lancet Diabetes & Endocrinology 11 (5), 345-361, 2023 | 55 | 2023 |
| Neuroendocrine tumors—less well known, often misunderstood, and rapidly growing in incidence A Chauhan, E Kohn, J Del Rivero JAMA oncology 6 (1), 21-22, 2020 | 54 | 2020 |
| Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia M Goswami, G Gui, LW Dillon, KE Lindblad, J Thompson, J Valdez, ... Journal for immunotherapy of cancer 10 (1), 2022 | 53 | 2022 |
| Advancing RAS/RASopathy therapies: an NCI‐sponsored intramural and extramural collaboration for the study of RASopathies AM Gross, M Frone, KW Gripp, BD Gelb, L Schoyer, L Schill, B Stronach, ... American Journal of Medical Genetics Part A 182 (4), 866-876, 2020 | 50 | 2020 |
